Sanofi defends proposed class action alleging improper Orange Book listings and sham patent litigation
Clients Sanofi-Aventis U.S. LLC
Jones Day is defending Sanofi-Aventis U.S. LLC against a proposed class action alleging that Sanofi improperly listed certain patents in the FDA's Orange Book and engaged in sham patent litigation to forestall competition for its diabetes drug, Lantus.
In re Lantus Direct Purchaser Antitrust Litigation, No. 16-cv-12652 (D. Mass.); No. 18-02086 (1st Cir.)